Back to News
Market Impact: 0.45

Veeva Systems Stock Down Despite Q3 Earnings & Revenues Top Estimates

VEEVMEDPISRGBSX
Corporate EarningsCorporate Guidance & OutlookCompany FundamentalsArtificial IntelligenceHealthcare & BiotechTechnology & InnovationAnalyst EstimatesInvestor Sentiment & Positioning
Veeva Systems Stock Down Despite Q3 Earnings & Revenues Top Estimates

Veeva Systems beat estimates in fiscal Q3 with revenue of $811.2M (+16% YoY) and adjusted EPS of $2.04, driven by 17.5% subscription growth to $682.5M and 13% growth in professional services; gross margin expanded to 75.4% and operating margin to 29.7%, with cash and short-term investments of $6.64B. Management raised FY26 guidance to $3.166–3.169B in revenue and $7.93 adjusted EPS (Q4 revenue guidance $807–810M; Q4 adj. EPS ~$1.92), pointed to accelerating adoption of Vault CRM and Development Cloud (23 new CRM customers, major enterprise rollouts) and roadmapped Veeva AI agents beginning in December as potential long-term value drivers. Despite the beats and upgraded outlook the stock fell ~6.1% after-hours; the quarter reinforces recurring subscription-led revenue and margin leverage while highlighting AI and platform expansion as key catalysts amid near-term market volatility.

Analysis

Veeva reported fiscal Q3 revenue of $811.2 million, up 16% year-over-year and 2.4% above the Zacks consensus, with adjusted EPS of $2.04 (+16.6% YoY) beating estimates by 4.62%. Subscription services, the recurring core, grew 17.5% to $682.5 million while professional services rose 13% to $128.7 million, underpinning a 30-basis-point gross-margin expansion to 75.4% and operating-margin improvement to 29.7% as operating profit rose 32.8% to $240.9 million. Management raised fiscal 2026 revenue guidance to $3,166–3,169 million (from $3,134–3,140 million) and lifted adjusted EPS to $7.93 (from $7.78), while Q4 revenue and EPS guidance also modestly topped consensus; cash and short-term investments increased to $6.64 billion and operating cash flow to $1.31 billion YTD. Notable expense moves include R&D up 11.3% and G&A up 56.1%, which temper the margin story and warrant monitoring despite overall operating leverage. Commercial and product catalysts include 23 new Vault CRM customers (115 live) and three top-20 biopharma enterprise wins for Development Cloud, plus management’s roadmap for Veeva AI agents with an initial CRM/commercial wave due in early December and broader agents in 2026. The market’s 6.1% after-hours selloff suggests investor caution on near-term execution or valuation despite strong fundamentals, making upcoming AI commercialization and large-scale rollouts key short-to-medium-term watchpoints.